American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with the society’s Transplant Infectious Diseases Special Interest Group to update its previ...

Check out new🔥
American Society for Transplantation Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients www.astctjournal.org/article/S266...
#IDsky #TxID #IDOnc

The #TxID team is growing and thriving! Grateful for this dedicated group—most pictured here—working to keep our transplant patients safe. Here’s to collaboration, curiosity, and camaraderie . 🌱🧬🦠 #IDSky #IDOnc #MedSky #MedMycoSky #ViroSky

@ishlt.bsky.social
@idsainfo.bsky.social
@astct.bsky.social

#TxID
#IDOnc
#IDSky
#MedMycoSky
#ViroSky
#MedSky

Please share:
@ishlt.bsky.social
@idsainfo.bsky.social
@astct.bsky.social

#TxID
#IDOnc
#IDSky
#MedMycoSky
#ViroSky
#MedSky

#TxID #IDSky #IDOnc 🙌🏽

📌 #IDOnc

In SHORTEN-2, immunocompromised hosts were not excluded if early clinical response and no unresolved source issues exist at randomization.
We hope to generate actionable data to guide the management of Pseudomonas BSI also in this population! 💪🏼
(🧵3/3) #AMSky #IDsky #TxID #IDOnc #ShorterIsBetter

We have evidence from several observational studies that show how, if adequately selected, uncomplicated infections may be safely treated with shorter courses, even in severely immunocompromised hosts like SOT or neutropenic patients.
(🧵2/3) #AMSky #IDsky #TxID #IDOnc

bsky.app/profile/jose...

#IDOnc

#IDOnc

#IDOnc

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

Sad to have had my last ‘in-person’ day as a physician at the @petermaccc.bsky.social, Melbourne! A fantastic place to practice, be inspired in #IDOnc #TxID and surrounded by #womeninSTEM! Will continue my PhD through the @ncicancer.bsky.social though, so many more return visits to come 🙌🏽

Strains of <i>Aspergillus fumigatus</i> Five Times More Likely To Acquire Resistance to Antifungals Researchers have identified strains of one of the world's most dangerous pathogens that are five times more likely to acquire antifungal resistance.

#IDOnc #medmycosky
www.technologynetworks.com/tn/news/stra...

Something cool and scary to read this morning.

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19 [Nov 3, 2022] @ZiadBakouny et al. @DrChoueiri @TMWiseDraper @COVID19nCCC @JAMAOnc jamanetwork.com/journals/jam... #COVID19nCancer #CCC19 #IDonc #ImmunoOnc #NCT04354701

COVID-19 vaccination and breakthrough infections in patients with cancer Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of antineoplastic systemic therapies can result in less robust antibody titers following vaccination and possible risk of breakthrough infection. As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history of cancer and those on active immunosuppression (including chemotherapy), limited evidence is available to inform the clinical efficacy of COVID-19 vaccination across the spectrum of patients with cancer.

COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer [Dec 24, 2021] @dr_aschmidt et al. @DrChoueiri @COVID19nCCC @Annals_Oncology ow.ly/tB9F50HiP4q #COVID19 #COVID19Vaccine #CCC19 #COVID19nCancer #IDonc

#IDOnc

#IDOnc

Prevention of infections including vaccination strategies in multiple myeloma [Oct 17, 2022] Ludwig & @myelomaMD onlinelibrary.wiley.com/doi/10.1002/... #mmsm #IDonc

Paper: Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study [12/724] Cheruvalath et al. @MeeraMohanMD #ASH24 Abst 256 ash.confex.com/ash/2024/web... #mmsm #IDonc #SuppOnc HT @RahulBanerjeeMD

Paper: A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma [Dec 7, 2024] @EagleMyeloma et al. #ASH24 Abst 255
ash.confex.com/ash/2024/web... #mmsm #IDonc

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis [Oct 10, 2023] @GemmaKReynolds et al. @benwteh @BloodAdvances ashpublications.org/bloodadvance... #IDonc #mmsm #caxtx

Redirecting

Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients [Sep 6, 2023] @benwteh et al. @TheLancetInfDis doi.org/10.1016/S147... #IDonc #leusm #lymsm #mmsm #mpnsm #caxtx

Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma [Jan 30, 2023] @Eddie_Cliff et al. @JCO_ASCO ascopubs.org/doi/full/10.... #mmsm #ImmunoOnc #IDonc

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

Multiple Myeloma IgG Level & Pneumococcal Vaccination Ab Response [Aug 10, 2017] @mtmdphd et al. @JPCRR ow.ly/I4tn30ejvTc #mmsm #ImmunoOnc #IDonc Consider: 1) homogeneous pop, 2/3) validating surrogate tests w/ outcomes, 4) larger n, 5) Epi + biomarker data

Multiple Myeloma IgG Level & Pneumococcal Vaccination Ab Response [Aug 10, 2017] @mtmdphd et al. @JPCRR ow.ly/I4tn30ejvTc #mmsm #ImmunoOnc #IDonc

Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study [4/25/17] Alemu et al. @JPCRR ow.ly/O8Dx30b9Wuc #mmsm #IDonc
58% PV in the past 5 years.
FV 15% optimal, 52% suboptimal & 33% none.
444 hospitalizations & $23M for 204 Pts over 2-year follow-up

Vaccination in Multiple Myeloma: Review of Current Literature [Jun 8, 2016] Alemu et al. @mtmdphd CLML ow.ly/AjF33016UUc #mmsm #ImmunoOnc #IDonc

Pneumococcal vaccine [PCV7 & PPV] responses in elderly Pts w/ MM, WM, MGUS [Oct 11, 2013] Karlsson et al. Trials in Vaccinology ow.ly/G4tzH #geriheme #mmsm #wmsm #IDonc More research needed into vax biology in B cell malignancies